New Publication: Reaksi Drug Safety News - Issue 3/2017

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

REAKSI Drug Safety News,

Issue 3/2017

 

  • Loperamide: Risk of Serious Cardiac Adverse Events with High Doses, Including Through Misuse
  • Thalidomide, Lenalidomide and Pomalidomide: Risk of Hepatitis B Reactivation, Herpes Zoster and Pulmonary Hypertension

 



 
 
  DOWNLOAD PDF


 

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Tuesday 13 November 2018, 11:21:38.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA